VNDA Vanda Pharmaceuticals Inc.

+0.31  (+1%)
Previous Close 22.42
Open 22.31
Price To Book 4.74
Market Cap 1190584785
Shares 52,379,445
Volume 457,589
Short Ratio 1.48
Av. Daily Volume 1,016,444

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181116264
  2. 8-K - Current report 181108192
  3. 8-K - Current report 181018964
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18986603
  5. 8-K - Current report 18985017

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due by end of 2018.
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Approved May 26, 2016.
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Phase 2 data released March 5, 2018 - primary endpoint met.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 initiated 4Q 2016. Data due by the end of 2018.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 trial initiated June 2018.
Atopic dermatitis
Phase 1 trial to commence 2H 2018.
Hematologic malignancies

Latest News

  1. An Investor’s Overview of Vanda Pharmaceuticals
  2. Insys Therapeutics: Recommendations and Market Capitalization
  3. Vanda Pharmaceuticals (VNDA) Catches Eye: Stock Jumps 8.7%
  4. Vanda Pharmaceuticals Announces Participation at Oppenheimer and Cantor Fitzgerald Fall 2018 Investor Conferences
  5. Here's Why The Stock Market Sold Off After The Fed Meeting
  6. Why Vanda Pharmaceuticals' Shares Are Soaring 10% Today
  7. The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial
  8. Rollins Set to Join S&P 500; Inogen to Join S&P MidCap 400; Vanda Pharmaceuticals and Garrett Motion to Join S&P SmallCap 600
  9. Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book
  10. Vanda Pharmaceuticals Inc (NASDAQ:VNDA): Commentary On Fundamentals
  11. HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment in Next Morning Performance
  12. Vanda Pharmaceuticals Announces Participation at September 2018 Investor Conferences
  13. Vanda Wins Denial of Petition For Rehearing on Fanapt®
  14. Vanda Pharmaceuticals Announces the Appointment of General Counsel
  15. Edited Transcript of VNDA earnings conference call or presentation 1-Aug-18 8:30pm GMT
  16. highlights: G-III Apparel Group, Rocky Brands, Vail Resorts, Vanda Pharmaceuticals and IntriCon
  17. Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2
  18. 5 Low-Beta Stocks to Take Refuge in a Volatile Market
  19. Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally
  20. featured highlights include: Vanda, Turtle Beach, PCM and Turning Point